---
title: "Haloperidol - Schizophrenia"
sidebar: mydoc_sidebar
permalink: db00502-mesh-d012559-1.html
toc: false 
---


Path ID: `DB00502_MESH_D012559_1`
{% include image.html url="images/db00502-mesh-d012559-1.png" file="db00502-mesh-d012559-1.png" alt="db00502-mesh-d012559-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D006220 | haloperidol | Drug |
| UniProt:P14416 | D(2) dopamine receptor | Protein |
| GO:0061527 | dopamine secretion, neurotransmission | BiologicalProcess |
| HP:0000709 | Psychosis | PhenotypicFeature |
| MESH:D012559 | Schizophrenia | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Haloperidol | NEGATIVELY REGULATES | D(2) Dopamine Receptor |
| D(2) Dopamine Receptor | POSITIVELY CORRELATED WITH | Dopamine Secretion, Neurotransmission |
| Dopamine Secretion, Neurotransmission | AFFECTS RISK FOR | Psychosis |
| Psychosis | MANIFESTATION OF | Schizophrenia |
|---------|-----------|---------|

Comment: Schizophrenia is theorized to be caused by a hyperdopaminergic state within the limbic system of the brain. So by inhibiting the binding of dopamine to its receptor, this drug may improve psychotic symptoms.

Reference: 
  - [https://pubchem.ncbi.nlm.nih.gov/compound/3559#section=Mechanism-of-Action](https://pubchem.ncbi.nlm.nih.gov/compound/3559#section=Mechanism-of-Action)
